Scancell Holdings Share Chat (SCLP)

I sent this e-mail to Cliff Holloway a few days ago..........................

Date: Friday, 8 November 2019 at 2:16 pm
To: Cliff Holloway
Subject: SCIB1 Trial

Dear Cliff,

Afternoon to you, to an end of another week, just under seven weeks to go to Xmas, where does the time go??

Cliff as you know, I would never even think of asking you a question that you cannot respond to, i.e. inside information, but there is something I would like to ask, which just perhaps you can respond to.

At the time the SCIB1 trial was announced, some four years ago, Keith Flaherty was down to be the Principle Investigator of Trial, which we all found exciting.. Can you tell me going back to January whilst awaiting the Approval for IND at the time we received Approval from the Regulatory body and Ethics Committee whether that would still be the case?? and indeed now if we were able to resubmit an IND would he still be involved in the trial??

Having seen so much data in the previous four years I think many of us would find that a major show of confidence in the trial if he was, and look forward to receiving your reply.

Hope all is well. have a nice weekend and all the best to you and Lindy for a couple of presentations this month. ATB

Paul

And checking my e-mails the last couple of days received this reply from CH........................

Cliff Holloway
Tue 12/11/2019 06:10
Hi Paul,

Apologies for the delay in responding. Keith Flaherty remains supportive of the SCIB1 programme and will continue to have an involvement subject to the IND of course.

Best regards,

Cliff

That was some day I missed yesterday, and I just noticed CFEP have come off the bid, leaving 3 MMs on 5p............No coincidence that whenever they takeup the bid and are on the ask we see those larger buys and sells. So hoping the 250k sells are the end of what has been a rather large line of shares.

With regard to the I-O Conference as Ray said............"".I don't think it is down to Vulpes.
IMO, it is down to Lindy's growing reputation within the scientific community"""

I would just add to that it is down to Lindy"s ever growing reputation that we have Vulpes on the board with their 16.67% holding and their commitment for the long term. It has actually only been 6 months since Vulpes came onto the scene, 5 years under the scrutiny of their Research Scientist and due diligence of the highest order. Just hoping this coming year we see Lindys and Scancells growing reputation reflected in the Share Price, which we have seen double and now return to the level they paid for their shares. In that respect looking forward to end of year updates on all fronts, but particularly I want to hear that we are ready now to resubmit our IND Application to the FDA for the SCIB 1 Trial, get patients dosed as soon as possible, and hoping too that Keith Flaherty will be the Priciple Trial Investigator in the U.S.A trials. That I am sure amongst a few other items will give us a huge boost going into 2020. Ah good to have my computer home!! GN

Maybe Botski, maybe Ray ? Who knows ?
Perhaps when the time comes there might be 6 'featured' in I O (E) ?
Better than a few 'Posters' in a 1000 IMO. It's good - more please . . .

I don't think it is down to Vulpes.
IMO, it is down to Lindy's growing reputation within the scientific community.

Do we think getting a featured presentation slot is down to Vulpes? Or has somebody else has realised Moditope is big news?

Crumbs thanks for that link 18.44 and as you found, Scancell's is 'the ONLY featured presentation' ! (ATM anyway). I'd guess Scancell can't choose that 'status' so the good news is - someone, somewhere else loves us ! Oh Joy !

IMO your words are worth repeating : "How has scancell not got a commercial deal yet with one of the big 'surrounding' players considering the competitiveness of this emerging market and the potential of scancells pipeline (33 targets for just the first 2 moditopes!).... still baffling".

Thanks Ray and Inan too . . . .

Nomlungu .... Bio Science Ltd

inventor of .... The sleeping pill you read ...

goodnight

I buy old poacher cheddar, not Oaxaca cheese, but I respect your choice to buy other cheese.

But 3 or 5 year old cheese made from unpasturised milk takes care.

Excellent reply so a stop-motion children's television series explains 5 or 14 strings? And analysis of the generated data from large data sets is #

Einstein combined the 2 theories to make Mexican String cheese. This was the forerunner of his unified field theory.

>I thought popes were not allowed to obfuscate<
But they are allowed to pontificate!

The Clangers used to eat string pudding. Probably where the theory evolved from. That and the Mexican Wave theory too.

I'm glad you got it.... but then again I knew you would :)

'that'll be the shape of it'

That made me smile crumbs - all of my interest in bioshares is related to shape theory. Discordant wave theory breeds other theories such as the Elliott Wave Theory.

Understanding life as part of a many dimensual anomaly leads to string theory and quantum mechanics - the secret to life and evolution is complicated.

I thought popes were not allowed to obfuscate

There will be newsflow though :).... can you predict the next RNS?

The answer will be there has been no sp shifting positive news and that there are still sellers... however there are still buyers too... anyone selling now is likely selling at a loss so 5p does indeed offer resistance... how long it will last? well... no newsflow and it will keep being tested but then it becomes a game of how many are willing to sell at a loss and how many are willing to keep buying or indeed looking to buy in.... that'll be the shape of it :)

Whilst inanaco and crumbs pontificate and obfuscate I just wonder why the share price is teasing the price payed buy Vulpes Life Sciences Fund?

data before deals is something we have been told by our BOD in past though I think more recently they have stepped a bit back from that .... We know most tiny bio companies get partnerships before they get data.... yet scancell has data and no commercial bio/pharma partners.... Of course still ever hopeful they just begin to appear one morning all kind of casually but we have been in this game a long long long time with no such action.... As I've said have to look at scancell as 3 parts the 3 platforms and failure to get a deal on one does not mean that will be same for others... all about pharma interest.... but yes also you need the team to successfully flog the goods!

except Ray spotted it ...

or they are confident enough to run a trial ...................

seems the obvious gets missed

So do I, but only leaning at present.
Another possible answer is "data before deals"

Crumbs : 2 possible answers, rubbish science or rubbish executive team. I lean towards the latter. .

The only FEATURED PRESENTATION

This has been in the media recently - they want more information to train their AI rules on [written mainly by white male westerners so of course there will be no inherent bias].

I have been part of data accretion projects - structuring data and refining the model is great but I have been treated at The Royal Free...

https://ai.google/healthcare/

https://www.theregister.co.uk/2019/09/19/five_nhs_trusts_do_data_deal_with_google_one_says_no/